Highest development stage: Phase 1

Development status: Active

Combination therapy

Mechanism of Action/Target pathogen: Disrupts the outer membrane by direct interaction with the lipid A component of the LPS and and disrupts the physical integrity of the phospholipid bilayer of the inner membrane, and possibly additional modes of action.